DaVita (NYSE:DVA - Get Free Report) posted its quarterly earnings results on Thursday. The company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.14 by $0.10, Zacks reports. DaVita had a net margin of 6.53% and a return on equity of 88.18%. DaVita updated its FY 2025 guidance to 10.200-11.300 EPS.
DaVita Price Performance
Shares of DVA stock traded down $20.11 during mid-day trading on Monday, hitting $156.95. 5,110,690 shares of the stock were exchanged, compared to its average volume of 534,172. The firm has a fifty day moving average of $161.39 and a 200 day moving average of $157.80. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. DaVita has a 52-week low of $118.56 and a 52-week high of $179.60. The company has a market cap of $12.87 billion, a PE ratio of 16.93, a price-to-earnings-growth ratio of 0.84 and a beta of 0.94.
Wall Street Analysts Forecast Growth
Separately, Barclays upped their price target on shares of DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $161.80.
View Our Latest Stock Analysis on DVA
About DaVita
(
Get Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
